QNRX
Quoin Pharmaceuticals, Ltd. [QNRX] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
QNRX Stock Summary
In the News
QNRX Financial details
Company Rating
-
Market Cap
760.16K
Income
-8.49M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
4
Optionable
No
Shortable
Yes
Earnings
06 May 2024
P/E
-0.55
Forward P/E
-
PEG
0.09
P/S
-
P/B
0.62
P/C
-
P/FCF
-0.72
Quick Ratio
3.05
Current Ratio
3.09
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-8.6
EPS next Y
-
EPS next Q
-
EPS this Y
-58.12%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
7.69%
-
-
-
-
SMA20
-20%
SMA50
-33.33%
SMA100
-55.56%
Inst Own
-
Inst Trans
-
ROA
-56%
ROE
-96%
ROC
-0.85%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-778%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.74-12.0
52W High
-
52W Low
-
RSI
44
Rel Volume
0.02
Avg Volume
627.53K
Volume
12.25K
Perf Week
-10.17%
Perf Month
-4.29%
Perf Quarter
-55.83%
Perf Half Y
-69.5%
-
-
-
-
Beta
1.953
-
-
Volatility
0.17%, 0.34%
Prev Close
1.92%
Price
4.24
Change
2.17%
Company Profile
- Volume Average 627.53K
- Market Capitalization 760.16K
- Employee 4
- CEO Dr. Michael Myers Ph.D.
- Headquarters Ashburn,VA,US
- IPO Date 2016-08-01
-
Website
https://quoinpharma.com 
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.
